ATARA Biotherapeutics (ATRA) Tops Q1 EPS by 6c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q1 EPS of ($0.86), $0.06 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $3.55 million versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Energy Fuels to acquire rare earth magnet maker VAC for $1.9 billion
• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates